Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational Study
Debdulal Chakraborty,1 Sudipta Das,2 Aniruddha Maiti,3 Tushar Kanti Sinha,1 Arnab Das,1 Jay Sheth,4 Subhendu Kumar Boral,1 Soumen Mondal,1 Krishnendu Nandi2 1Disha Eye Hospitals, Kolkata, India; 2Nethralayam Superspeciality Eye Care, Kolkata, India; 3Global Eye Hospitals, Kolkata, India; 4Department...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-01-01
|
| Series: | Clinical Ophthalmology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/clinical-evaluation-of-faricimab-in-real-world-diabetic-macular-edema--peer-reviewed-fulltext-article-OPTH |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584066908553216 |
|---|---|
| author | Chakraborty D Das S Maiti A Sinha TK Das A Sheth J Boral SK Mondal S Nandi K |
| author_facet | Chakraborty D Das S Maiti A Sinha TK Das A Sheth J Boral SK Mondal S Nandi K |
| author_sort | Chakraborty D |
| collection | DOAJ |
| description | Debdulal Chakraborty,1 Sudipta Das,2 Aniruddha Maiti,3 Tushar Kanti Sinha,1 Arnab Das,1 Jay Sheth,4 Subhendu Kumar Boral,1 Soumen Mondal,1 Krishnendu Nandi2 1Disha Eye Hospitals, Kolkata, India; 2Nethralayam Superspeciality Eye Care, Kolkata, India; 3Global Eye Hospitals, Kolkata, India; 4Department of Retina Services, Shantilal Shanghvi Eye Institute (SSEI), Mumbai, IndiaCorrespondence: Debdulal Chakraborty, Department of Vitreo-retinal Services, Disha Eye Hospitals, 88 Ghosh Para Road Barrackpore, Kolkata, West Bengal, 700120, India, Tel +91 33 6636 0000, Email devdc@rediffmail.comPurpose: To evaluate the efficacy of faricimab in real-world clinical settings in India for treating diabetic macular edema (DME) in treatment-naïve and recalcitrant eyes.Patients and Methods: This retrospective study involved 39 eyes (16 treatment-naive and 23 recalcitrant) treated with intravitreal faricimab at four centers in India. Patients received three monthly loading doses followed by a pro-re-nata regimen, with outcomes measured for best-corrected visual acuity (BCVA), central macular thickness (CMT), intraretinal fluid (IRF), subretinal fluid (SRF), and hyperreflective foci (HRF).Results: Significant improvements in BCVA were observed in both treatment-naïve and recalcitrant groups, with greater gains in the naïve group (p< 0.001). Overall, BCVA improved from 0.48 logMAR to 0.27 logMAR (P< 0.001), and 59% of eyes gained more than 10 ETDRS letters and 41% gaining > 15 ETDRS letters. Both groups showed significant reduction in CMT, with the naïve group achieving greater reduction (P< 0.001). The overall CMT reduction was statistically significant at 6 months (P< 0.001). Resolution of IRF and SRF was achieved in both groups, with SRF reducing from 82.1% to 20.5% (P< 0.001) and IRF from 87.2% to 17.9% (P< 0.001). Significant reductions in HRF were also observed across both inner (P< 0.001) and outer retinal layers (P< 0.001). No ocular or systemic adverse events were reported.Conclusion: Faricimab treatment resulted in significant improvements in visual acuity and anatomical outcomes in both treatment-naïve and recalcitrant DME eyes, highlighting its potential as a valuable therapeutic option in diverse clinical settings. Further real-world studies are warranted to establish long-term efficacy and safety.Keywords: diabetic macular edema, anti VEGF, faricimab |
| format | Article |
| id | doaj-art-5a04f1a73bd14315a7893aed155a5035 |
| institution | Kabale University |
| issn | 1177-5483 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj-art-5a04f1a73bd14315a7893aed155a50352025-01-27T18:05:34ZengDove Medical PressClinical Ophthalmology1177-54832025-01-01Volume 1926927799615Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational StudyChakraborty DDas SMaiti ASinha TKDas ASheth JBoral SKMondal SNandi KDebdulal Chakraborty,1 Sudipta Das,2 Aniruddha Maiti,3 Tushar Kanti Sinha,1 Arnab Das,1 Jay Sheth,4 Subhendu Kumar Boral,1 Soumen Mondal,1 Krishnendu Nandi2 1Disha Eye Hospitals, Kolkata, India; 2Nethralayam Superspeciality Eye Care, Kolkata, India; 3Global Eye Hospitals, Kolkata, India; 4Department of Retina Services, Shantilal Shanghvi Eye Institute (SSEI), Mumbai, IndiaCorrespondence: Debdulal Chakraborty, Department of Vitreo-retinal Services, Disha Eye Hospitals, 88 Ghosh Para Road Barrackpore, Kolkata, West Bengal, 700120, India, Tel +91 33 6636 0000, Email devdc@rediffmail.comPurpose: To evaluate the efficacy of faricimab in real-world clinical settings in India for treating diabetic macular edema (DME) in treatment-naïve and recalcitrant eyes.Patients and Methods: This retrospective study involved 39 eyes (16 treatment-naive and 23 recalcitrant) treated with intravitreal faricimab at four centers in India. Patients received three monthly loading doses followed by a pro-re-nata regimen, with outcomes measured for best-corrected visual acuity (BCVA), central macular thickness (CMT), intraretinal fluid (IRF), subretinal fluid (SRF), and hyperreflective foci (HRF).Results: Significant improvements in BCVA were observed in both treatment-naïve and recalcitrant groups, with greater gains in the naïve group (p< 0.001). Overall, BCVA improved from 0.48 logMAR to 0.27 logMAR (P< 0.001), and 59% of eyes gained more than 10 ETDRS letters and 41% gaining > 15 ETDRS letters. Both groups showed significant reduction in CMT, with the naïve group achieving greater reduction (P< 0.001). The overall CMT reduction was statistically significant at 6 months (P< 0.001). Resolution of IRF and SRF was achieved in both groups, with SRF reducing from 82.1% to 20.5% (P< 0.001) and IRF from 87.2% to 17.9% (P< 0.001). Significant reductions in HRF were also observed across both inner (P< 0.001) and outer retinal layers (P< 0.001). No ocular or systemic adverse events were reported.Conclusion: Faricimab treatment resulted in significant improvements in visual acuity and anatomical outcomes in both treatment-naïve and recalcitrant DME eyes, highlighting its potential as a valuable therapeutic option in diverse clinical settings. Further real-world studies are warranted to establish long-term efficacy and safety.Keywords: diabetic macular edema, anti VEGF, faricimabhttps://www.dovepress.com/clinical-evaluation-of-faricimab-in-real-world-diabetic-macular-edema--peer-reviewed-fulltext-article-OPTHdiabetic macular edemaanti vegffaricimab |
| spellingShingle | Chakraborty D Das S Maiti A Sinha TK Das A Sheth J Boral SK Mondal S Nandi K Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational Study Clinical Ophthalmology diabetic macular edema anti vegf faricimab |
| title | Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational Study |
| title_full | Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational Study |
| title_fullStr | Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational Study |
| title_full_unstemmed | Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational Study |
| title_short | Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational Study |
| title_sort | clinical evaluation of faricimab in real world diabetic macular edema in india a multicenter observational study |
| topic | diabetic macular edema anti vegf faricimab |
| url | https://www.dovepress.com/clinical-evaluation-of-faricimab-in-real-world-diabetic-macular-edema--peer-reviewed-fulltext-article-OPTH |
| work_keys_str_mv | AT chakrabortyd clinicalevaluationoffaricimabinrealworlddiabeticmacularedemainindiaamulticenterobservationalstudy AT dass clinicalevaluationoffaricimabinrealworlddiabeticmacularedemainindiaamulticenterobservationalstudy AT maitia clinicalevaluationoffaricimabinrealworlddiabeticmacularedemainindiaamulticenterobservationalstudy AT sinhatk clinicalevaluationoffaricimabinrealworlddiabeticmacularedemainindiaamulticenterobservationalstudy AT dasa clinicalevaluationoffaricimabinrealworlddiabeticmacularedemainindiaamulticenterobservationalstudy AT shethj clinicalevaluationoffaricimabinrealworlddiabeticmacularedemainindiaamulticenterobservationalstudy AT boralsk clinicalevaluationoffaricimabinrealworlddiabeticmacularedemainindiaamulticenterobservationalstudy AT mondals clinicalevaluationoffaricimabinrealworlddiabeticmacularedemainindiaamulticenterobservationalstudy AT nandik clinicalevaluationoffaricimabinrealworlddiabeticmacularedemainindiaamulticenterobservationalstudy |